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Background. The clinical importance of low-level mupirocin resistance and genotypic chlorhexidine resistance
remains unclear. We aimed to determine whether resistance to these agents increases the risk of persistent
methicillin-resistant Staphylococcus aureus (MRSA) carriage after their use for topical decolonization therapy.
Methods. A nested case-control study was conducted of MRSA carriers who received decolonization therapy
from 2001 through 2008. Cases, patients who remained colonized, were matched by year to controls, those in whom
MRSA was eradicated (follow-up, 2 years). Baseline MRSA isolates were tested for mupirocin resistance by Etest and
chlorhexidine resistance by qacA/B polymerase chain reaction. MRSA carriers with high-level mupirocin resistance
were excluded. The effect of the primary exposure of interest, low-level mupirocin and genotypic chlorhexidine
resistance, was evaluated with multivariate conditional logistic regression analysis.
Results. The 75 case patients and 75 control patients were similar except that those persistently colonized were older
(P 5 .007) with longer lengths of hospital stay (P 5 .001). After multivariate analysis, carriage of combined low-level
mupirocin and genotypic chlorhexidine resistance before decolonization independently predicted persistent MRSA
carriage (odds ratio [OR], 3.4 [95% confidence interval {CI}, 1.5–7.8]). Other risk factors were older age (OR, 1.04 [95%
CI, 1.02–1.1]), previous hospitalization (OR, 2.4 [95% CI, 1.1–5.7]), presence of a skin wound (OR, 5.7 [95% CI, 1.8–
17.6]), recent antibiotic use (OR, 3.1 [95%CI, 1.3–7.2]), and central venous catheterization (OR, 5.7 [95%CI, 1.4–23.9]).
Conclusions. Combined low-level mupirocin and genotypic chlorhexidine resistance significantly increases the
risk of persistent MRSA carriage after decolonization therapy. Institutions with widespread use of these agents
should monitor for resistance and loss of clinical effectiveness.
Colonization with methicillin-resistant Staphylococcus
aureus (MRSA) increases the risk of adverse health
outcomes, with 10%–30% of carriers subsequently
developing MRSA infection [1, 2]. MRSA carriers also
add to the colonization pressure in healthcare facilities,
acting as reservoirs for transmission to other patients
[3]. MRSA control interventions have therefore in-
cluded therapies to eradicate colonization, and recent
studies have shown that this strategy can be successful
[4]. There are concerns, however, regarding the emer-
gence of resistance to agents used for this purpose.
Intranasal mupirocin and chlorhexidine washing are
widely used to decolonize MRSA carriers [4]. Increasing
resistance to these agents is being reported [5–8].
Low-level mupirocin-resistant MRSA isolates, defined
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by minimum inhibitory concentrations (MICs) between 8 and
256 lg/mL, have mutations in native tRNA synthetase [9, 10].
High-level mupirocin-resistant isolates (MICs $ 512 lg/mL)
harbor a plasmid-encoded mupA gene [9, 10]. Chlorhexidine
resistance is associated with plasmid-borne qacA/B genes that
code for multidrug efflux pumps [11], resulting in at least 2- to
4-fold increases in minimum bactericidal concentrations [12,
13].
Previous studies have concluded that high-level mupirocin
resistance is associated with decolonization failure [14–16].
However, the elevated MICs that result in low-level mupirocin
resistance and minimum bactericidal concentrations associated
with qacA/B gene carriage remain well below concentrations
achieved in vivo, which suggests that they may be clinically
unimportant. Studies evaluating low-level mupirocin resistance
have been underpowered to detect a significant association with
decolonization failure [14, 15, 17]. A recent report suggested
that MRSA strains carrying the qacA/B genes may be transmitted
more rapidly [13]. Thus, the clinical relevance of low-level
mupirocin resistance and genotypic chlorhexidine resistance
remains unclear [9, 18].
The University of Geneva Hospitals has been using intranasal
mupirocin and chlorhexidine bathing to decolonize MRSA
carriers since 1994 [19]. The prevalence of mupirocin resistance
in MRSA was noted to steadily increase from 9% in 1999 to 81%
in 2008. MIC testing in 2008 showed that .99% of resistant
MRSA isolates had low-level mupirocin resistance, and a sample
of 12 nonclonal low-level mupirocin-resistant isolates all pos-
sessed the V588F point mutation associated with this resistance
phenotype [20]. Thus, we aimed to determine whether low-level
mupirocin resistance and chlorhexidine resistance are associated
with persistent MRSA carriage after decolonization therapy with
these agents by conducting a nested case-control study of MRSA




The University of Geneva Hospitals is a tertiary care center with
1901 beds and 47,706 admissions in 2009. MRSA screening is
performed for patients with a history of MRSA carriage or who
are hospitalized in the intensive care unit, for contacts of newly
identified carriers, and for patients who are about to be trans-
ferred to rehabilitation facilities. Universal screening at admission
previously occurred hospital-wide from January through August
2003 and in surgical wards from July 2004 throughMay 2006 [21,
22]. Screening swab samples are collected from the nares, groin,
and other clinically indicated sites [19]. MRSA carriers routinely
receive decolonization therapy consisting of intranasal mupirocin
twice daily for 5 days and chlorhexidine bathing (4% Lifo-Scrub;
B. Braun) daily for 7 days. Topical mupirocin is applied in-
tranasally only, and not to skin or catheter exit sites. Systemic
antibiotics are not used for decolonization therapy. Patients are
rescreened for MRSA daily for 3 days after decolonization
treatment, then weekly if they remain MRSA negative. All MRSA
isolates from newly identified MRSA carriers were routinely
stored at –70C until June 2005. MRSA strains isolated from
sterile sites and strains with unusual phenotypic or genotypic
characteristics were stored during the entire study period.
Study Design and Sample Selection
The nested case-control study was conducted between 2001 and
2008. This time period was chosen because of the availability of
electronic medical records. Patients with MRSA isolates stored
during the study period were eligible for inclusion. Patients were
also required to have received at least 3 days of decolonization
therapy within 4 weeks after the sampling date of their stored
isolate and to have provided at least 1 post-decolonization
MRSA screening sample or clinical culture 1–12 months after
decolonization therapy.
Patients were excluded if they carried high-level mupirocin-
resistant MRSA before decolonization. Patients who had re-
ceived decolonization therapy within the past 6 months were also
excluded, because we were interested in evaluating patients who
had not been recently exposed to eradication therapies. Exoge-
nous recolonization, rather than persistent colonization with the
same strain, was also an exclusion criterion. This was determined
by examining pre- and post-decolonization MRSA isolates for
changes in antibiotic sensitivities, staphylococcal cassette chro-
mosome (SCC) mec classification, or multiple-locus variable
number of tandem repeats analysis (MLVA) pattern.
The primary study outcome was failure of decolonization ther-
apy as documented by at least 1 positive MRSA screening result
or clinical culture result 1–12 months after decolonization ther-
apy. This outcome defined the patient as a potential case patient.
Control patients were patients who had successfully eradicated
their MRSA carriage as strictly defined by at least 6 consecutive
negative MRSA swab samples if the last follow-up sample was
obtained ,2 years after decolonization therapy or only negative
MRSA swab samples if the last sample was collected $2 years
after attempted eradication. Patients were followed up for 2 years.
Any positive MRSA culture result (screening or clinical) during
the follow-up period made the patient a potential case patient.
Successful eradication was the rarer outcome; thus, all eligible
control patients were included. One case patient was randomly
selected for each control patient and frequency matched by year
of decolonization to control for time as a potential confounder.
Microbiological Methods
MRSA screening specimens from individual patients were
pooled in the laboratory and inoculated directly and after
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overnight enrichment onto MRSA ID plates (bioMe´rieux).
Identification and antibiotic susceptibility testing of MRSA from
colonies suggestive of staphylococci were performed using
standard methods [21] according to Clinical and Laboratory
Standards Institute recommendations [23] and confirmed with
multiplex quantitative polymerase chain reaction (PCR) for the
genes femA and mecA [24].
Baseline MRSA isolates, collected prior to decolonization
therapy, were screened for mupirocin resistance using a 0.5
McFarland suspension on Mueller-Hinton agar with a 5-lg disk
(Becton Dickinson) incubated at 35C for 18–24 h [25]. Re-
sistance was defined as a zone of inhibition of ,14 mm. Re-
sistant isolates underwent MIC determination with Etests (AB
Biodisk) [26]. MIC breakpoints were defined as susceptible,
#4 lg/mL; low-level resistant, 8–256 lg/mL; and high-level
resistant, $512 lg/mL [9, 10].
Phenotypically mupirocin-resistant isolates underwent mupA
PCR to detect the gene encoding high-level resistance, and all
baseline isolates were tested with an assay for the V588F point
mutation, which confers low-level resistance. The presence of
the qacA/B genes was assessed for all baseline isolates (see Ap-
pendix 1 for details of the molecular methods, including primer
and probe sequences). SCC mec determination was performed
for all pre-decolonization and available post-decolonization
isolates [27]. Stored isolates from samples that had been col-
lected from patients before and after decolonization therapy
were typed by means of MLVA consisting of a multiplex PCR
using 10 primer pairs. Representative isolates of all MLVA
clusters were selected and subjected to multilocus sequence
typing as previously reported [28].
Data Collection
Data regarding demographic characteristics and risk factors for
persistent MRSA carriage were collected retrospectively from
electronic medical records. Variables included age, sex, admission
date, admission department, comorbidities, McCabe score [29],
length of stay, hospitalization during the past 2 years, nursing
home residency, presence of skin wounds, previous MRSA
infection, surgical procedure during hospitalization, receipt of
antibiotics during the hospitalization prior to decolonization, and
presence of devices during decolonization therapy. The Infection
Control Program database was used to obtain prospectively col-
lected decolonization therapy details [19]. MRSA culture and
sensitivity results were obtained from the laboratory information
system. The study was approved by the hospital institutional
review board (approval no. MED 09-057R).
Statistical Analysis
Baseline characteristics were compared with the Student t test
or Wilcoxon test as appropriate for continuous variables. For
differences in proportions, the v2 test was used. Odds ratios
using Mantel-Haenszel methods matching by year were
calculated for risk factors for persistent MRSA carriage.
Multivariate conditional logistic regression analysis, group-
matched by year, was conducted using variables with P , .2
on univariate analysis. Likelihood ratio tests were used with
a significance level of P 5 .05 to guide sequential exclusion of
covariates from the model. Interaction terms were tested to
assess for effect modification. All P values were 2-tailed, and
a P value of #0.05 was considered to reveal a statistically
significant difference. Results were analyzed using Stata, ver-
sion 11.0 (StataCorp).
RESULTS
Patient Characteristics and Decolonization Details
A flowchart showing the sample selection process is presented in
Figure 1. There were 13,556 MRSA isolates stored from 5094
patients between 2001 and 2008. Of these, 2469 patients (48%)
received decolonization therapy for$3 days within 1 month after
providing the specimen from which their stored isolate originated
and were eligible for study inclusion. After exclusions for receipt of
decolonization therapy during the past 6 months, inadequate
post-decolonization follow-up, contaminated and/or nonviable
baseline MRSA isolates, high-level mupirocin resistance, and
changes in antibiotic sensitivities, SCCmec type, orMLVA pattern
after decolonization, a total of 75 control patients were identified
and matched to 75 case patients by year of decolonization.
Characteristics of case patients and control patients are shown
in Table 1. Those persistently colonized after eradication therapy
(case patients) were older than those successfully decolonized
(control patients) (median age, 76 vs 68 years; P 5 .01). Case
patients also had greater lengths of stay than control patients
(median, 49 vs 27 days; P 5 .001). Pre-decolonization MRSA
isolates from case patients were more likely to carry SCC mec
type I (P 5 .001; Table 2), compared with those from controls,
in which SCC mec type IV was more common (P 5 .03). The
median duration of decolonization therapy was 7 days in both
groups (P 5 .77). There was no difference in the department
where decolonization therapy was administered, number of
screening samples collected after decolonization therapy, and
time to the last follow-up screening or clinical sample after the
end of therapy.
Risk Factors for Persistent MRSA Colonization
Low-level mupirocin resistance was found in MRSA isolates
from 49 (64%) of 75 case patients and 26 (35%) of 75 control
patients prior to decolonization (P , .001; Table 3). Genotypic
chlorhexidine resistance was more common than mupirocin
resistance, with 68 case patients (91%) and 51 control patients
(68%) carrying MRSA with the qacA/B genes (P , .001). In
almost all instances, low-level mupirocin resistance coexisted
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with genotypic chlorhexidine resistance. Only 1 of the case pa-
tients had a baseline MRSA isolate that was resistant to mu-
pirocin and not to chlorhexidine, and there were none among
the control patients. Therefore, for further analyses, the com-
bination of resistance to both agents was taken as the exposure
of interest.
After multivariate analysis, the presence of both low-level
mupirocin resistance and genotypic chlorhexidine resistance at
baseline remained strongly associated with persistent MRSA
colonization after eradication therapy, with an adjusted odds
ratio (aOR) of 3.4 (95% confidence interval [CI], 1.5–7.8;
P5 .004; Table 4). Other independent risk factors for persistent
colonization were older age (aOR, 1.04 per 1-year increment
[95% CI, 1.02–1.1; P 5 .001), prior hospitalization (aOR, 2.4
[95% CI, 1.1–5.7]; P 5 .04), presence of skin wounds (aOR,
5.7 [95% CI, 1.8–17.6]; P5 .003), receipt of antibiotics inactive
against MRSA (aOR, 3.1 [95%CI, 1.3–7.2]; P5 .01), and central
venous catheterization during decolonization therapy (aOR, 5.7
[95% CI, 1.4–23.9]; P 5 .02). There was no effect modification
of SCCmec type on the association between combined low-level
mupirocin and genotypic chlorhexidine resistance and failure of
decolonization.
Genotypic Analyses and Resistance After Decolonization
All low-level mupirocin-resistant isolates contained SCC mec
type I and the V588F point mutation. Interestingly, the mupA
gene, usually associated with high-level mupirocin resistance,
was present in all low-level resistant isolates with MIC $ 64 lg/
mL. This represented low-level mupirocin-resistant isolates from
12 (24%) of 49 case patients and 2 (8%) of 26 control patients.
Forty-six of 75 case patients had post-decolonization culture
isolates stored and available for further evaluation. MLVA typ-
ing of pre- and post-decolonization isolate pairs from these
patients were identical, consistent with MRSA persistence or
relapse rather than exogenous recolonization. Among these 46
case patients, 7 (15%) had mupirocin-sensitive isolates at
baseline and developed resistance (5 low-level and 2 high-level
resistance) after decolonization. In addition, 3 case patients
(7%) had low-level mupirocin-resistant MRSA at baseline and
high-level mupirocin-resistant MRSA after decolonization. All 3
Figure 1. Study population and sample selection for the case-control study.
Mupirocin and Chlorhexidine Resistance d CID 2011:52 (15 June) d 1425
case patients were colonized with MRSA carrying both the
V588F point mutation and mupA gene at baseline.
Induced expression of themupA gene resulting in a high-level
resistant phenotype possibly occurred in vivo during de-
colonization therapy in MRSA strains from the 12 case patients
and 2 control patients whose baseline isolates carried this gene.
The univariate and multivariate conditional regression analyses
were therefore repeated excluding these patients and rematching
the remaining case patients and control patients by year (see
Appendix 2). After these exclusions, the presence of combined
low-level mupirocin and genotypic chlorhexidine resistance re-
mained an independent risk factor for failure of decolonization
therapy (aOR, 3.2 [95% CI, 1.3–7.6]; P 5 .01).
DISCUSSION
Controlling MRSA transmission and infection is important in
healthcare facilities, and decolonization is often recommended to
achieve this goal (strength of evidence, IB–II [30]). However, the
results of this study emphasize the need to exercise caution when
using this strategy. Our findings demonstrate that carriage of
MRSA with both low-level mupirocin resistance and genotypic
chlorhexidine resistance is strongly associated with persistent
colonization after eradication therapy. Resistance to both these
agents was closely linked in our study. Thus, it was difficult to
separate the effects of resistance to individual agents. Genotypic
chlorhexidine resistance alone did not predict persistent carriage,
suggesting that the combination of low-level mupirocin and
chlorhexidine resistance may be necessary to result in clinical
failure. These agents are often recommended and commonly
administered concurrently forMRSA eradication [4, 30, 31]; thus,
our findings are likely to have important clinical implications.
Mupirocin resistance has been reported in 65% of MRSA
isolates in 1 study [5], but the relative contribution of low- and
high-level resistance was not determined. Another study found
low-level mupirocin resistance in only 18.6% of their MRSA
isolates [32]. Higher rates were found in our institution. In
contrast, rates of genotypic chlorhexidine resistance comparable
to that seen in our institution have been described previously, in
63% of isolates in Europe [11] and up to 80% of isolates






Age, median years (IQR) 76 (64–83) 68 (45–81) .01
Male sex 39 (52) 43 (57) .51
Admission department .27
Internal medicine 32 (43) 24 (32) .18
Surgery 28 (37) 27 (36) .87
Intensive care 5 (7) 7 (9) .55
Pediatrics 0 (0) 3 (4) .08
Othera 10 (13) 14 (19) .37
Comorbidities
Cardiovascular disease 42 (56) 34 (45) .19
Chronic pulmonary disease 13 (17) 12 (16) .83
Chronic renal failure 13 (17) 7 (9) .15
Requirement of hemodialysis 2 (3) 0 (0) .16
Diabetes mellitus 13 (17) 12 (16) .83
Chronic liver disease 9 (12) 10 (13) .81
Neurological disease 27 (36) 19 (24) .11
Malignant disease 15 (20) 11 (15) .39
Autoimmune disease 3 (4) 0 (0) .08
HIV/AIDS 2 (3) 4 (5) .41
Intravenous drug use 1 (1) 3 (4) .31
Chronic skin disease 4 (5) 6 (8) .51
McCabe score
1 44 (59) 48 (64) .50
2 25 (33) 25 (33) ..99
3 6 (8) 2 (3) .15
Length of stay, median days (IQR) 49 (23–94) 27 (10–49) .001
NOTE. Data are no. (%) of patients, unless otherwise specified. HIV, human immunodeficiency virus; IQR, interquartile range.
a Includes Dermatology, Psychiatry, Rehabilitation, Intermediate Care, and Outpatient Departments.
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elsewhere [8]. This is of particular concern in view of increasing
chlorhexidine use, not only for MRSA control but also for
a variety of other indications [31], as well as reports of possible
antibiotic cross-resistance with chlorhexidine [33]. Our high
resistance rates are likely due to selection of resistant strains. The
V588F mutation, seen in all low-level mupirocin-resistant
MRSA in this study, is not associated with substantial fitness
costs [34]. In addition, MRSA strains that carry the qacA/B genes
have the potential for increased transmission when chlorhex-
idine-based surface antiseptic protocols are used [13]. These
factors may explain why resistant strains were able to pre-
dominate in our institution where targeted decolonization of
MRSA carriers has been routine for more than 15 years.
As far as we are aware, this is the first study demonstrating an
association between both low-level mupirocin and genotypic
chlorhexidine resistance and persistent MRSA carriage after de-
colonization therapy. Previous research studying low-level
mupirocin resistance has suggested its possible link with persis-
tent MRSA colonization [14, 17]. Because of small patient
numbers, these studies were unable to make firm conclusions
about the relevance of low-level resistance. In addition, the du-
ration of follow-up was short (#4 weeks). Other studies have
observed relapse 2–12 months after therapy [15, 16, 35, 36]. To
ensure that case patients and control patients were classified
correctly, we used a strict definition for MRSA eradication and
patients were followed up for 2 years. The large sample of pa-
tients with resistant MRSA, a long-standing MRSA storage pol-
icy, and prospectively collected decolonization data enabled this
study to detect a significant association between resistance to
agents for eradication therapy and persistentMRSA colonization.
Other independent risk factors for persistent MRSA coloni-
zation in this study were older age, previous hospitalization, skin
wounds, recent antibiotic use, and central venous catheterization.
These factors have been described previously [16, 17, 35, 36] and
Table 2. Methicillin-Resistant Staphylococcus aureus (MRSA) Culture and Decolonization Details
Characteristic Case patients (n 5 75) Control patients (n 5 75) P
Duration of MRSA carriage before decolonization, median days (IQR) 5 (4–6) 5 (4–7) .27
Patients MRSA positive on the basis of samples collected in month
before decolonization
At screeninga 66 (88) 64 (85) .63
At clinical culturea 24 (32) 15 (20) .09
Molecular characteristics of MRSA isolates from samples
collected in month before decolonization
SCC mec classification .03
Type I 67 (89) 50 (67) .001
Type IV 5 (7) 14 (19) .03
Other 3 (4) 11 (14) .03
MLST sequence type .01
ST228 65 (87) 49 (65) .002
ST8 5 (7) 8 (11) .38
ST5 5 (7) 6 (8) .75
ST22 0 (0) 4 (5) .04
ST7 0 (0) 3 (4) .08
Other 0 (0) 5 (7) .02
Details of decolonization therapy
Duration, median days (IQR) 7 (7–7) 7 (7–7) .77
Department of decolonization administration .25
Internal medicine 19 (25) 23 (31) .47
Surgery 28 (37) 26 (35) .73
ICU 4 (5) 1 (1) .17
Pediatrics 0 (0) 3 (4) .08
Otherb 24 (32) 22 (29) .72
Patients who underwent decolonization therapy during past 12 months 1 (1) 0 (0) .32
Samples collected #2 years after decolonization
No. of screening samples, median (IQR) 10 (7–16) 9 (6–14) .36
Time to last follow-up sample, median days (IQR) 234 (107–483) 284 (132–472) .81
NOTE. Data are no. (%) of patients, unless otherwise specified. ICU, intensive care unit; IQR, interquartile range; MLST, multi-locus sequence typing; SCC,
staphylococcal cassette chromosome.
a These groups are not mutually exclusive. Patients may have had positive results on both screening and clinical cultures during the month prior to decolonization.
b Includes Dermatology, Psychiatry, Rehabilitation, Intermediate Care, and Outpatient Departments.
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may in part reflect reduced ability to effectively administer
eradication therapies and endogenous recolonization from ex-
tranasal sites where topical therapy may have reduced efficacy,
such as wounds or devices. Adherence to and quality of de-
colonization therapy administration has been associated with
success of eradication [37, 38]. This information was not available
retrospectively. However, the presence of comorbidities and the
department where decolonization was administered were used as
proxy measures for this parameter and no difference in these
variables was seen between case patients and control patients.
There are limitations to this study. The strict definitions for
case patients and control patients resulted in the exclusion of
patients who did not provide specimens on multiple occasions
after eradication therapy. Thus, there is potential for selection
bias from inclusion of patients with multiple comorbidities
and frequent healthcare contact. Decolonization success rates
are higher among relatively healthy MRSA carriers at our
institution, compared with that of our study population [39].
Therefore, the association between resistance and de-
colonization failure may be underestimated in the current
Table 3. Risk Factors Associated With Failure of Decolonization-Univariate Analysis









Low-level resistancea 49 (64) 26 (35) 3.4 (1.7–7.1) ,.001
Genotypic resistance
mupA geneb 12/49 (24) 2/26 (8) 5.1 (1.0–25.8) .03
V588F point mutation 52 (69) 26/73 (36)c 4.6 (2.1–9.9) ,.001
Chlorhexidine resistance
qacA/B genes 68 (91) 51 (68) 10.2 (2.6–40.7) ,.001
Resistance combinations
Fully sensitive 6 (8) 24 (32) 0.1 (.01–.3) ,.001
Low-level mupirocin resistance only 1 (1) 0 (0) .32
Genotypic chlorhexidine resistance only 21 (28) 25 (33) 0.7 (0.3–1.6) .44
Resistance to mupirocin and chlorhexidine 47 (63) 26 (35) 3.2 (1.6–6.5) .001
Hospitalization during past 2 years 54 (72) 40 (53) 2.3 (1.1–4.6) .02
Nursing home residence during past 6 months 21 (28) 18 (24) 1.2 (0.6–2.5) .58
Wound or pressure sore 19 (25) 8 (11) 2.8 (1.1–6.7) .02
Previous MRSA infection 2 (3) 0 (0) .16
Surgery during hospitalization 39 (52) 34 (45) 1.3 (0.7–2.5) .41
Antibiotic use
MRSA-active antibiotic 19 (25) 18 (24) 1.1 (0.5–2.3) .85
MRSA-inactive antibiotic 53 (71) 39 (52) 2.2 (1.1–4.3) .02
Devices present
Central venous catheter 14 (19) 5 (7) 3.0 (1.1–8.4) .03
Urinary catheter 21 (28) 8 (11) 3.3 (1.3–8.3) .01
NOTE. Data are no. (%) of patients, unless otherwise specified. CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio.
a These patients carried MRSA with low-level mupirocin resistance determined by Etest minimum inhibitory concentrations.
b The mupA gene polymerase chain reaction was performed in low-level mupirocin-resistant isolates only.
c The allelic discrimination assay was indeterminate in MRSA isolates from 2 patients.
Table 4. Independent Risk Factors Associated With Failure of Decolonization-Multivariate Analysis
Risk factor Adjusted OR (95% CI) P
Combined mupirocin and chlorhexidine resistance 3.4 (1.5–7.8) .004
Age (per 1-year increment) 1.04 (1.02–1.1) .001
Prior hospitalization (previous 2 years) 2.4 (1.1–5.7) .04
Wound or pressure sore 5.7 (1.8–17.6) .003
Exposure to MRSA-inactive antibiotic 3.1 (1.3–7.2) .01
Central venous catheterization 5.7 (1.4–23.9) .02
NOTE. Only risk factors found to be statistically significant on multivariate analysis are shown. CI, confidence interval; MRSA, methicillin-resistant
Staphylococcus aureus; OR, odds ratio.
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study, in which control patients were more likely to experience
a failure of eradication therapy than the general population of
MRSA carriers in our facility, including healthy carriers of
community-associated MRSA [39]. Misclassification of cases
may have occurred as a result of exogenous recolonization. Al-
though we attempted to identify this by means of MLVA typing,
we may not have identified all instances of recolonization with
the same endemic strain. Information regarding samples pro-
cessed outside the hospital was unavailable. This may also have
caused the misclassification of some patients. However, our in-
stitution is the only public hospital for our catchment pop-
ulation; therefore, the majority of patients were likely followed
up within our facility for ongoing medical care. In addition,
there was no significant difference in follow-up between case
patients and control patients in terms of frequency of sampling
and time to last post-decolonization sample. Thus, the likelihood
of differential misclassification is low. Although there are po-
tential biases in this study, the strength of the effect estimate
makes these factors less likely explanations for our findings.
MRSA control is a priority in healthcare facilities, and erad-
ication of carriage can be beneficial for the individual, as well as
for patients at risk of MRSA acquisition. However, with any
intervention using antimicrobial agents, the risk of emergence of
resistance is invariably a potential threat. In this study of MRSA-
colonized inpatients, carriage of strains with combined low-level
mupirocin and genotypic chlorhexidine resistance significantly
increased the risk of persistent MRSA carriage after de-
colonization therapy. Therefore, widespread use of de-
colonization therapies should be coupled with procedures to
monitor for emergence of resistance. Alternative agents or
practices are required in settings where resistance has rendered
this MRSA control measure ineffective.
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